Last reviewed · How we verify
Molgramostim nebulizer solution
At a glance
| Generic name | Molgramostim nebulizer solution |
|---|---|
| Also known as | Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), rhGM-CSF |
| Sponsor | Savara Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). (PHASE3)
- Molgramostim Nebulizer Solution Expanded Access Program Protocol
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PHASE3)
- Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (PHASE3)
- GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia (PHASE2)
- Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PHASE2)
- Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection (PHASE2)
- Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Molgramostim nebulizer solution CI brief — competitive landscape report
- Molgramostim nebulizer solution updates RSS · CI watch RSS
- Savara Inc. portfolio CI